Close Menu

NEW YORK – The Salk Institute and BrigeBio Pharma announced a three-year collaboration on Wednesday to advance the institute's cancer research.

BridgeBio will fund research at the Salk Cancer Center over the next three years, with the goal of developing new precision oncology treatments based on the institute's research into genetically validated drug targets. The partners did not disclose the funding amount.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Qiagen

The Phosphoinositide 3-Kinase (PI3K) pathway is one of the most frequently altered pathways in human cancer and plays a significant role in disease progression and resistance to endocrine therapy.